Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 136-144 , March 2010

Dose Intensified Molecular Targeted Radiotherapy for Cancer—Lymphoma as a Paradigm

  • Gerald DeNardo, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Gerald L. DeNardo, MD, 1508 Alhambra Blvd, Room 3100, Sacramento, CA 95816
    • ,
  • Sally DeNardo, MD

References 

  1. Ehrlich P, Herter CA. Ueber einige Verwendungen der Napthochinonsulfosaure. Z Physiol Chem. 1904;61:379–392
  2. Pressman D, Korngold L. The in vivo localization of anti-Wagner-osteogenic sarcoma antibodies. Cancer. 1953;6:619–623
  3. Ettinger DS, Dragon LH, Klein J, et al. Isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer (A case report). Cancer Treat Rep. 1979;63:131–134
  4. Kohler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497
  5. Carrasquillo JA, Krohn KA, Beaumier P, et al. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep. 1984;68:317–328
  6. Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980;40:3147–3154
  7. Miller RA, Maloney DG, Warnke R, et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517–522
  8. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers. 1987;2:49–53
  9. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconj Radiophar. 1988;1:17–33
  10. DeNardo GL, DeNardo SJ, O'Grady LF, et al. Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res. 1990;50(suppl 3):1014–1016
  11. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989;7:1027–1038
  12. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833
  13. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453–2463
  14. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918–3928
  15. Goodwin DA, Meares CF. Pretargeting: General principles; October 10-12, 1996. Cancer. 1997;80(suppl 12):2675–2680
  16. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med. 2005;11:1250–1255
  17. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results. Cancer Biother Radiopharm. 2000;15:15–29
  18. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934–2942
  19. Press OW, Unger JM, Braziel RM, et al. A phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. Blood. 2003;102:1606–1612
  20. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1023–1030
  21. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–1006
  22. Rappaport H, Winter WI, Hicks EB. Follicular lymphoma: A re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer. 1956;9:792–821
  23. Lukes RF, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer. 1974;34:1488–1503
  24. Lennert K, Mohri N, Stein H, et al. The histopathology of malignant lymphoma. Br J Haematol. 1975;31:193–204
  25. The Non-Hodgkin's Lymphoma Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112–2135
  26. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392
  27. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987–994
  28. Horning SJ. Treatment approaches to the low-grade lymphomas. Blood. 1994;83:881–884
  29. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol. 1986;4:1470–1480
  30. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336–340
  31. Richman CM, DeNardo SJ, O'Donnell RT, et al. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibodies 170H.82 with autologous stem cell support and cyclosporin A. Clin Cancer Res. 1999;5(suppl 10):3243s–3248s
  32. Wong JYC, Somlo G, Odom-Maryon T, et al. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin Cancer Res. 1999;5:3224s–3231s
  33. Kapadia NS, Engles JM, Wahl RL. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med. 2008;49:674–678
  34. Skvortsova I, Popper BA, Skvortsov S. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res. 2005;46:241–248
  35. Coiffer B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  36. Witzig TE, White CA, Gordon LI. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263–1270
  37. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262–3269
  38. Morschhauser F, Radford J, Van Hoof A, et al. Phase III Trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156–5164
  39. Kaminski M, Tuck M, Regan D. High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine I-131. Blood. 2002;100:356a
  40. Ghobrial I, Witzig T. Radioimmunotherapy: A new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology. 2004;18:623–630
  41. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 1995;55(suppl 23):5899s–5907s
  42. Juweid ME, Stadtmauer E, Hajjar G, et al. Pharmacokinetics, dosimetry and initial therapeutic results with 131I- and 111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody (MAb) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Clin Cancer Res. 1999;5(suppl):3292s–3303s
  43. DeNardo GL, DeNardo SJ, Lamborn KR, et al. Low-dose fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm. 1998;13:239–254
  44. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246–3256
  45. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974–1981
  46. Wiseman GA, White CA, Witzig TE, et al. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res. 1999;5(suppl 10):3281s–3286s
  47. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457–470
  48. Emmanouilides C, Witzig TE, Wiseman GA, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 2007;22:684–691
  49. DeNardo GL. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med. 2005;35:202–211
  50. DeNardo GL, Sysko VV, DeNardo SJ. Cure of incurable lymphoma. Int J Radiat Oncol Biol Phys. 2006;66:S46–S56
  51. Borghaei H, Wallace S, Schilder RJ. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma. 2004;5(suppl 1):16–21
  52. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence and design considerations in fractionated radioimmunotherapy. Cancer. 2002;94:1332–1348
  53. Ansell SM, Ristow KM, Habermann TM. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3885–3890
  54. Wahl RL. Tositumomab 131I therapy in non-Hodgkin's lymphoma. J Nucl Med. 2004;46:128S–140S
  55. DeNardo GL, DeNardo SJ, Macey DJ, et al. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model. Cancer. 1994;73(suppl 3):1038–1048
  56. Liersch T, Meller J, Kulle B, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-Labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J Clin Oncol. 2005;23:6763–6770
  57. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm. 2001;16:305–315
  58. Zalutsky MR. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. J Nucl Med. 2006;47:1238–1240
  59. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: Recent results and future directions. J Clin Oncol. 1996;14:1383–1400
  60. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693–713
  61. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic radiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  62. Schrier DM, Stemmer SM, Johnson T, et al. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: A phase I trial. Cancer Res. 1995;55:5921s–5924s
  63. Macey DJ, Grant EJ, Kasi LP, et al. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: A phase II trial. Clin Cancer Res. 1997;3:1547–1555
  64. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705–1711
  65. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270–3278
  66. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin's lymphoma: A multivariable cohort analysis. Blood. 2003;102:2351–2357
  67. Meredith RF, Khazaeli MB, Liu T, et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med. 1992;33:1648–1653
  68. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst. 1990;82:763–771
  69. DeNardo DA, DeNardo GL, Yuan A, et al. Prediction of radiation doses from therapy using tracer studies with iodine-131 labeled antibodies. J Nucl Med. 1996;37:1970–1975
  70. Shen S, DeNardo GL, DeNardo SJ, et al. Reproducibility of operator processing for radiation dosimetry. Nucl Med Biol. 1997;24:77–83
  71. Stabin MG. Update: The case for patient-specific dosimetry in radionuclide therapy. Cancer Biother Radiopharm. 2008;23:273–284
  72. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed refractory B-cell non-Hodgkin lymphoma: Update results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–1266
  73. Wiseman GA, White CA, Witzig TA, et al. Final dosimetry results of IDEC-Y2B8 phase I/II 90yttrium radioimmunotherapy trial on non-Hodgkin's lymphoma (NHL). J Nucl Med. 1999;40:64P
  74. DeNardo GL, DeNardo SJ, Kukis DL, et al. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study. Anticancer Res. 1998;18:2779–2788
  75. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med. 2003;44:465
  76. Sharkey RM. The direct route may not be the best way to home. J Nucl Med. 2005;46:391–394
  77. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 2000;97:1802–1807
  78. Weiden PL, Breitz HB. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit Rev Oncol Hematol. 2001;40:37–51
  79. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535–2543
  80. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823–834
  81. Goldenberg DM, Sharkey RM. Novel radiolabeled antibody conjugates. Oncogene. 2007;26:3734–3744
  82. Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA. 2006;103:6841–6846
  83. Goldenberg DM, Rossi EA, Sharkey RM, et al. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008;49:158–163
  84. Hok S, Natarajan A, Balhorn R, et al. Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia. Bioconjug Chem. 2007;18:912–921
  85. West J, Perkins J, Hok S, et al. Direct antilymphoma activity of novel, first-generation “antibody mimics” that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer Biother Radiopharm. 2006;21:645–654
  86. Balhorn R, Hok S, Burke P, et al. Selective high affinity ligand antibody mimics for cancer diagnosis and therapy: Initial application to lymphoma/leukemia. Clin Cancer Res. 2007;13(suppl 18):5621s–5628s
  87. DeNardo GL, Natarajan A, Hok S, et al. Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging. Cancer Biother Radiopharm. 2008;23:783–795
  88. DeNardo GL, Mirick GR, Hok S, et al. Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia. Int J Oncol. 2009;34:511–516
  89. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188–2195
  90. DeNardo GL, Kroger LA, DeNardo SJ, et al. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer. 1994;73:1012–1022
  91. Griffiths GL, Govindan SV, Sharkey RM, et al. 90Y-DOTA-hLL2: An agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med. 2003;44:77–84
  92. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. J Clin Oncol. 1998;16:2780–2795

 Supported by National Cancer Institute PO1-CA47829.

PII: S0001-2998(09)00103-2

doi: 10.1053/j.semnuclmed.2009.10.005

Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 136-144 , March 2010

Article Tools

* Image Usage & Resolution